Zepbound Generic / Tirzepatide Biosimilar: When Will It Be Available? (2026 Status)

Short answer: there is no FDA-approved generic Zepbound or generic tirzepatide as of 2026-05-09, and there will not be one for years. Eli Lilly is the only sponsor of tirzepatide. Generic competition becomes possible when Lilly's composition-of-matter and method-of-use patents expire — the relevant Orange Book listings extend exclusivity into the mid-2030s. Compounded tirzepatide from licensed 503A pharmacies is also no longer protected by the FDA's enforcement-discretion grace period (which ended October 2024 for tirzepatide). Here is the regulatory framework and what cash-pay patients should know.

Why is there no generic Zepbound in 2026?

Three reasons:

1. Patent protection. Eli Lilly holds composition-of-matter and method-of-use patents on tirzepatide listed in the FDA Orange Book. These patents establish a window of market exclusivity during which generic ANDAs (Abbreviated New Drug Applications) cannot obtain FDA approval to market the same active ingredient for the same indication. The relevant patent listings extend into the mid-2030s based on the original 2014–2015 filing dates plus method-of-use extensions. Specific patent expiration dates require USPTO + Orange Book look-up because the practical generic-availability date depends on which patent expires first plus any pediatric exclusivity extensions.
2. FDA regulatory pathway. Tirzepatide is a chemically synthesized modified peptide — NOT a biologic. That means it is regulated under a New Drug Application (NDA) rather than a Biologics License Application (BLA). Generics are theoretically possible via the standard Hatch-Waxman ANDA pathway (the same path Hikma used for generic liraglutide / Victoza, FDA-approved December 2024, and Teva used for generic liraglutide / Saxenda, launched August 27, 2025). This is different from Trulicity (dulaglutide), which IS a biologic on a BLA — Trulicity can only have biosimilars via the 351(k) pathway, and none have been approved.
3. Manufacturing complexity. Even when patents expire, generic competitors must demonstrate chemistry/manufacturing/controls (CMC) equivalence to the reference Zepbound product. Tirzepatide is a 39-amino-acid modified peptide with a fatty-acid side chain — significantly more complex to manufacture at scale than a small-molecule drug like phentermine. The lead time from patent expiration to first ANDA approval is typically 2-5 years for this class of drug.

Can there be a Zepbound biosimilar?

No — not in the regulatory sense of the word. “Biosimilar” specifically refers to follow-on versions of biologic drugs regulated under the 351(k) pathway. Tirzepatide is regulated under an NDA (Hatch-Waxman pathway), not as a biologic. Follow-on tirzepatide products will be generics, not biosimilars. The distinction matters because the regulatory framework, the interchangeability rules, and the patent-listing mechanics differ between the two.

For comparison: Trulicity (dulaglutide) IS a biologic (Fc fusion protein on a BLA), so any follow-on dulaglutide would be a biosimilar via 351(k). None has been approved as of 2026-05-09.

Compounded tirzepatide status (2026)

Compounded tirzepatide from licensed 503A pharmacies was widely available in 2024 under the FDA's enforcement-discretion grace period that applied while tirzepatide was on the FDA Drug Shortage List. That status changed in October 2024:

• October 2, 2024: FDA declared the tirzepatide shortage resolved.
• October 7, 2024: Outsourcing Facility Association sued FDA challenging the resolution decision.
• December 19, 2024: FDA reaffirmed the shortage resolution. Compounded tirzepatide enforcement discretion ended for 503A pharmacies; 503B outsourcing facilities had a slightly later compliance window.
• 2025-2026: Patient access to compounded tirzepatide narrowed dramatically. Some compounders pivoted to non-API peptide formulations or to slightly modified variants (e.g., tirzepatide + B12) on the theory that modifications take the product outside the standard enforcement scope. The FDA has issued warning letters to some of these compounders.

For the parallel timeline on compounded semaglutide, see our compounded semaglutide provider directory — semaglutide's grace period ended February 2025, three months after tirzepatide's.

What the liraglutide generic timeline tells us

Two generic liraglutides have launched in the US — these are the closest precedents for what tirzepatide's eventual generic timeline might look like:

• Hikma generic liraglutide (Victoza): FDA-approved + launched December 2024. The first generic GLP-1 receptor agonist in the US. References Victoza for type 2 diabetes (NDA 022341, approved January 2010 — so ~14 years from brand approval to generic launch).
• Teva generic liraglutide (Saxenda): Launched August 27, 2025. First generic GLP-1 RA approved for chronic weight management. References Saxenda (NDA 206321, approved December 2014 — so ~11 years from brand approval to generic launch).

Tirzepatide's NDA approval dates are May 2022 (Mounjaro) and November 2023 (Zepbound). If the 11–14-year liraglutide timeline is a guide, the earliest reasonable generic tirzepatide window would be the early-to-mid 2030s — but composition-of-matter patents and any pediatric/orphan exclusivity extensions are the binding constraint, not the approval-to-generic interval.

Tirzepatide patent landscape at a glance

The chart anchors three structural facts. (1) Liraglutide generics are the closest precedent and took 11–14 years from brand NDA approval to first US generic launch. (2) Tirzepatide's US composition-of-matter patent (the binding constraint on ANDA approval) is listed in the FDA Orange Book with expiration in the mid-2030s — we use 2036 as the conservative anchor, but the exact date depends on which Lilly Orange Book listing the FDA treats as controlling and whether pediatric or method-of-use extensions apply. (3) International generic tirzepatide is already emerging in India and similar markets, but those products are not legally importable into the US and the FDA does not recognize foreign-manufactured generics without an approved ANDA. For the parallel cliff view across every other branded GLP-1, see our GLP-1 generic timeline & patent cliff tracker .

Cash-pay alternatives in the interim

Until a generic tirzepatide arrives, cash-pay options for patients seeking tirzepatide-equivalent therapy in 2026:

• Brand Zepbound via LillyDirect Self Pay Journey Program: $299 (2.5 mg vial) / $399 (5 mg vial) / $449 (7.5–15 mg vials) per month — verified live 2026-05-09. KwikPen runs $299–$699 by strength.
• Brand Zepbound at Sam's Club KwikPen: $299 (2.5 mg) / $399 (5 mg) / $499 (7.5 mg) / $699 (10/12.5/15 mg). Free same-day refrigerated delivery for Plus members.
• Wegovy (semaglutide, different molecule but same weight-management indication): NovoCare self-pay $299/month standard pen; oral pill $149/month. Less weight-loss efficacy than tirzepatide per SURMOUNT-5 (NEJM 2025) head-to-head, but cheaper and same FDA indication. See our Wegovy vs Mounjaro decision guide for the molecule-vs-molecule context.
• Foundayo (orforglipron, oral GLP-1, FDA-approved April 2026): $149/month at LillyDirect / Amazon Pharmacy. Oral pill, less weight-loss data so far than tirzepatide, but cheapest brand-name FDA-approved weight-management option.
• Insurance + copay savings card: as little as $25/month for Zepbound for commercially insured patients. See Cigna PA guide and Aetna PA guide for the verbatim payer policy criteria.
• Compounded tirzepatide (regulatory caveat): Some 503A pharmacies continue to dispense compounded tirzepatide despite the FDA enforcement-discretion period ending. The legal status is contested. We do NOT recommend specific grey-market vendors. For the verified provider directory of compounded tirzepatide, see compounded tirzepatide providers — but check each provider's current regulatory standing before purchasing.

Practical takeaways

• No FDA-approved generic tirzepatide as of 2026-05-09. Eli Lilly is the only sponsor.
• The earliest reasonable generic window is the early-to-mid 2030s based on patent and regulatory-pathway timelines. Specific dates require USPTO + Orange Book verification.
• “Biosimilar” is the wrong word for tirzepatide. Tirzepatide is regulated under an NDA, not a BLA, so follow-on tirzepatide will be a generic (351(j) pathway), not a biosimilar (351(k) pathway). Trulicity (dulaglutide) IS a biologic and could have biosimilars — but none has been approved.
• Compounded tirzepatide enforcement discretion ended October 2024. 503A pharmacies are no longer protected for compounding standard tirzepatide. Some compounders continue dispensing on regulatory theories that are being actively contested.
• The two generic liraglutides (Hikma Dec 2024, Teva Aug 2025) are precedent. Generic GLP-1 RAs can clear the ANDA pathway — the 11–14-year approval-to- generic interval for liraglutide suggests tirzepatide generics are a future-decade event, not a 2026-2028 event.
• For now, the cheapest brand-name option is Foundayo ($149/month at LillyDirect / Amazon Pharmacy) for chronic weight management. Different molecule, oral instead of injectable, less efficacy data so far.
• If your insurance dropped Zepbound (CVS Caremark July 2025 swap, BMI clawback, or denial), the realistic non-generic alternatives are Wegovy, Foundayo, and cash-pay brand Zepbound — not a future generic. Our Zepbound alternatives 2026: the Caremark-displaced edition walks the rank-ordered alternative list, the cross-trial efficacy caveats (Wegovy is NOT equivalent to Zepbound), and the insurance-appeal path to get Zepbound back on formulary for patients whose prescription was OSA-anchored or for whom Wegovy is intolerable.
• If you are buying compounded tirzepatide online right now, run a four-check verification first. Because there is no FDA-approved generic and the enforcement-discretion period ended in October 2024, the online tirzepatide market includes a meaningful share of grey-market vendors. Our buying tirzepatide online: how to verify pharmacy legitimacy guide walks through LegitScript, NABP .pharmacy, FDA Warning Letters, and State Board of Pharmacy lookup — plus the diagnostic red flags (DSHEA supplement disclaimers, direct-Stripe checkout with no medical intake, ToS “if applicable” prescription carve-outs) that distinguish grey-market from legitimate compounded telehealth.

Further reading

• Top tirzepatide weight-loss studies (curated PubMed reading list)
• Top tirzepatide questions on Reddit, answered